409 related articles for article (PubMed ID: 29239031)
1. Molecular alterations of neuroendocrine tumours of the lung.
Rossi G; Bertero L; Marchiò C; Papotti M
Histopathology; 2018 Jan; 72(1):142-152. PubMed ID: 29239031
[TBL] [Abstract][Full Text] [Related]
2. Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities.
Swarts DR; Ramaekers FC; Speel EJ
Biochim Biophys Acta; 2012 Dec; 1826(2):255-71. PubMed ID: 22579738
[TBL] [Abstract][Full Text] [Related]
3. [Pulmonary neuroendocrine tumors in the new WHO 2015 classification: Start of breaking new grounds?].
Schnabel PA; Junker K
Pathologe; 2015 May; 36(3):283-92. PubMed ID: 25956813
[TBL] [Abstract][Full Text] [Related]
4. Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D.
Simbolo M; Mafficini A; Sikora KO; Fassan M; Barbi S; Corbo V; Mastracci L; Rusev B; Grillo F; Vicentini C; Ferrara R; Pilotto S; Davini F; Pelosi G; Lawlor RT; Chilosi M; Tortora G; Bria E; Fontanini G; Volante M; Scarpa A
J Pathol; 2017 Mar; 241(4):488-500. PubMed ID: 27873319
[TBL] [Abstract][Full Text] [Related]
5. [Pulmonary neuroendocrine tumors and preneoplasic lesions].
Rouquette Lassalle I
Ann Pathol; 2016 Jan; 36(1):34-43. PubMed ID: 26776366
[TBL] [Abstract][Full Text] [Related]
6. Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm.
Pelosi G; Bianchi F; Dama E; Simbolo M; Mafficini A; Sonzogni A; Pilotto S; Harari S; Papotti M; Volante M; Fontanini G; Mastracci L; Albini A; Bria E; Calabrese F; Scarpa A
Virchows Arch; 2018 Apr; 472(4):567-577. PubMed ID: 29388013
[TBL] [Abstract][Full Text] [Related]
7. An in-silico analysis reveals further evidence of an aggressive subset of lung carcinoids sharing molecular features of high-grade neuroendocrine neoplasms.
Pelosi G; Melocchi V; Dama E; Hofman P; De Luca M; Albini A; Gemelli M; Ricotta R; Papotti M; La Rosa S; Uccella S; Harari S; Sonzogni A; Asiedu MK; Wigle DA; Bianchi F
Exp Mol Pathol; 2024 Feb; 135():104882. PubMed ID: 38237798
[TBL] [Abstract][Full Text] [Related]
8. Pathology and diagnosis of neuroendocrine tumors: lung neuroendocrine.
Travis WD
Thorac Surg Clin; 2014 Aug; 24(3):257-66. PubMed ID: 25065926
[TBL] [Abstract][Full Text] [Related]
9. Mutational analysis of pulmonary tumours with neuroendocrine features using targeted massive parallel sequencing: a comparison of a neglected tumour group.
Vollbrecht C; Werner R; Walter RF; Christoph DC; Heukamp LC; Peifer M; Hirsch B; Burbat L; Mairinger T; Schmid KW; Wohlschlaeger J; Mairinger FD
Br J Cancer; 2015 Dec; 113(12):1704-11. PubMed ID: 26645239
[TBL] [Abstract][Full Text] [Related]
10. Advances in neuroendocrine lung tumors.
Travis WD
Ann Oncol; 2010 Oct; 21 Suppl 7():vii65-71. PubMed ID: 20943645
[TBL] [Abstract][Full Text] [Related]
11. hASH1 is a specific immunohistochemical marker for lung neuroendocrine tumors.
Ye B; Cappel J; Findeis-Hosey J; McMahon L; Yang Q; Xiao GQ; Xu H; Li F
Hum Pathol; 2016 Feb; 48():142-7. PubMed ID: 26596584
[TBL] [Abstract][Full Text] [Related]
12. Molecular markers help characterize neuroendocrine lung tumors.
Rusch VW; Klimstra DS; Venkatraman ES
Ann Thorac Surg; 1996 Sep; 62(3):798-809; discussion 809-10. PubMed ID: 8784011
[TBL] [Abstract][Full Text] [Related]
13. What clinicians are asking pathologists when dealing with lung neuroendocrine neoplasms?
Pelosi G; Fabbri A; Cossa M; Sonzogni A; Valeri B; Righi L; Papotti M
Semin Diagn Pathol; 2015 Nov; 32(6):469-79. PubMed ID: 26561395
[TBL] [Abstract][Full Text] [Related]
14. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid.
Travis WD; Rush W; Flieder DB; Falk R; Fleming MV; Gal AA; Koss MN
Am J Surg Pathol; 1998 Aug; 22(8):934-44. PubMed ID: 9706973
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic modifications of histone h4 in lung neuroendocrine tumors.
Li F; Ye B; Hong L; Xu H; Fishbein MC
Appl Immunohistochem Mol Morphol; 2011 Oct; 19(5):389-94. PubMed ID: 21415707
[TBL] [Abstract][Full Text] [Related]
16. Morphologic and molecular classification of lung neuroendocrine neoplasms.
Metovic J; Barella M; Bianchi F; Hofman P; Hofman V; Remmelink M; Kern I; Carvalho L; Pattini L; Sonzogni A; Veronesi G; Harari S; Forest F; Papotti M; Pelosi G
Virchows Arch; 2021 Jan; 478(1):5-19. PubMed ID: 33474631
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive Characterization of the Genomic Landscape in Chinese Pulmonary Neuroendocrine Tumors Reveals Prognostic and Therapeutic Markers (CSWOG-1901).
Peng W; Cao L; Chen L; Lin G; Zhu B; Hu X; Lin Y; Zhang S; Jiang M; Wang J; Li J; Li C; Shao L; Du H; Hou T; Chen Z; Xiang J; Pu X; Li J; Xu F; Loong H; Wu L
Oncologist; 2022 Mar; 27(2):e116-e125. PubMed ID: 35641209
[TBL] [Abstract][Full Text] [Related]
18. ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival.
Skov BG; Holm B; Erreboe A; Skov T; Mellemgaard A
J Thorac Oncol; 2010 Apr; 5(4):453-9. PubMed ID: 20104194
[TBL] [Abstract][Full Text] [Related]
19. Malignancy-associated X chromosome allelic losses in foregut endocrine neoplasms: further evidence from lung tumors.
D'Adda T; Bottarelli L; Azzoni C; Pizzi S; Bongiovanni M; Papotti M; Pelosi G; Maisonneuve P; Antonetti T; Rindi G; Bordi C
Mod Pathol; 2005 Jun; 18(6):795-805. PubMed ID: 15578070
[TBL] [Abstract][Full Text] [Related]
20. [CGH findings in neuroendocrine tumours of the lung].
Johnen G; Krismann M; Jaworska M; Müller KM
Pathologe; 2003 Jul; 24(4):303-7. PubMed ID: 14513278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
